I now have comprehensive material from three authoritative sources. Let me compile the full answer.
Schizophrenia
Sources: Kaplan & Sadock's Comprehensive Textbook of Psychiatry, Goldman-Cecil Medicine, Goodman & Gilman's Pharmacological Basis of Therapeutics
Definition
Schizophrenia is the prototypical psychotic disorder, characterized by:
- Positive symptoms (hallucinations, delusions)
- Negative symptoms (affective flattening, abulia, apathy, social withdrawal)
- Disorganized symptoms (disorganized speech and behavior)
- Cognitive impairment
- Major impairment in one or more areas of functioning (occupational, interpersonal, self-care)
No single sign or symptom by itself justifies the diagnosis - the pattern and combination of symptoms matters.
Epidemiology
| Feature | Data |
|---|
| Lifetime prevalence | Slightly less than 1% |
| Annual incidence | ~15 per 100,000 (marked variability across populations) |
| Peak onset | Late adolescence to young adulthood |
| Sex difference | Slightly more common in males; earlier onset in males than females |
| Life expectancy | Shortened by 10-15 years |
| Suicide risk (lifetime) | ~5-6% |
Etiology and Pathobiology
The pathogenesis of schizophrenia remains unknown and is multifactorial.
Genetic Factors
- Twin studies show genetic factors account for up to 50% of risk
- Multiple gene loci are involved (highly heterogeneous)
- Large number of severe ultrarare mutations related to synaptic plasticity
- Higher concordance in monozygotic twins for negative symptoms than positive symptoms
- Increased familial risk for negative and disorganization symptoms over psychotic symptoms
Neuropathology
- Nongliotic neuropathologic process with subtle disruptions of cortical cytoarchitecture
- Postmortem brain studies reveal these subtle abnormalities (distinguishing it from neurodegenerative conditions)
- Considerable neuroimaging evidence supports cerebral dysfunction
- Frontal lobe abnormalities correlate particularly with negative symptoms
Neurotransmitter Hypotheses
Dopamine Hypothesis (most established):
- All clinically effective antipsychotic drugs have high affinity for D2 dopamine receptors
- Psychostimulants that increase extracellular dopamine can induce or worsen psychosis in schizophrenic patients
- Subcortical DA hyperfunction (especially striatum) → positive symptoms (respond well to antipsychotics)
- Prefrontal cortex DA hypofunction (mesocortical pathway) → negative and cognitive symptoms (treatment-refractory)
Glutamate:
- Glutamatergic systems also play an important role in psychotic symptom production
- NMDA receptor hypofunction is implicated (this explains why NMDA antagonists like PCP mimic schizophrenia)
Neurodevelopmental Theory
- A non-localizable brain lesion is either present at birth or acquired early in life
- Psychosocial factors and neurodevelopment interact with this lesion
- Psychosocial stressors can precipitate exacerbations and worsen the overall course
DSM-5 TR Diagnostic Criteria
Criterion A - Two or more of the following for a significant portion of time during a 1-month period (at least one must be 1, 2, or 3):
- Delusions
- Hallucinations
- Disorganized speech (derailment, incoherence)
- Grossly disorganized or catatonic behavior
- Negative symptoms (diminished emotional expression, avolition)
Criterion B - Level of functioning in work, interpersonal relations, or self-care is markedly below pre-onset level
Criterion C - Duration of at least 6 months (including at least 1 month of Criterion A symptoms; may include prodromal/residual phases)
Criterion D - Schizoaffective disorder and depressive/bipolar disorder with psychotic features ruled out
Criterion E - Not due to substance or medication effects
Criterion F - Not better explained by autism spectrum disorder or communication disorder
Note: ICD-11 requires only a minimum duration of 1 month (not including prodromal phase)
Core Symptom Domains
1. Psychotic Symptoms (Positive Symptoms)
Hallucinations:
- Perceptions without external stimuli - most commonly auditory (hearing voices)
- Voices may provide a running commentary, refer to the patient in third person, or give commands
- Schneiderian first-rank symptoms: hearing one's thoughts spoken aloud (écho de la pensée), voices referring to oneself, a running commentary - these were historically considered pathognomonic but are now known to occur in other disorders too
- Hallucinations can occur in any sensory modality (auditory most common; visual, tactile, olfactory also seen)
Delusions:
- Fixed, false beliefs held despite contradictory evidence
- Persecutory delusions most common
- Referential delusions - belief that neutral events/objects have special personal significance
- Delusions of control/passivity - belief that thoughts, feelings, or actions are controlled by external forces
- Other types: grandiose, religious, somatic, nihilistic, erotomanic
2. Negative Symptoms (Five Core Categories - NIMH MATRICS Consensus)
| Negative Symptom | Description |
|---|
| Avolition | Inability to initiate and persist in goal-directed activities |
| Anhedonia | Inability to experience pleasure from normally pleasurable activities |
| Asociality | Lack of interest in social interactions |
| Affective blunting | Reduced facial expression, vocal expression, expressive gestures |
| Alogia | Poverty of speech; sparse, brief, empty responses |
Key clinical points about negative symptoms:
- Associated with: male gender, poor premorbid function, earlier onset, longer duration of untreated illness
- Correlate with frontal lobe dysfunction and neuropathology
- Greater genetic heritability than positive symptoms
- More reliably associated with outcome than positive symptoms
- Reciprocal relationship with affective symptoms (more prominent affective symptoms = milder negative symptoms)
3. Disorganization Symptoms
Disorganized speech (formal thought disorder):
- Loose associations (derailment) - ideas slip off the track
- Tangentiality - replies to questions obliquely, never reaching the point
- Circumstantiality - excessive irrelevant detail before reaching the point
- Incoherence (word salad) - speech lacks logical connections
- Poverty of thought - little information conveyed
- Neologisms - invented words
- Echolalia - meaningless repetition of another's words
Disorganized behavior:
- Difficulty performing goal-directed activities
- Inappropriate affect
- Impulsive, unpredictable behavior
4. Motor Symptoms and Catatonia
Motor symptoms:
- Repetitive hand movements, complex purposeless movements
- Mannerisms (odd caricature of normal movements)
- Echopraxia (mimicking others' movements)
- Rocking, hand-wringing
Catatonia (separate specifier in DSM-5 TR):
- "Marked decrease in reactivity to the environment"
- Requires ≥3 of 12 motor signs: stupor, catalepsy, waxy flexibility, mutism, negativism, posturing, mannerism, stereotypy, agitation, grimacing, echolalia, echopraxia
- Lifetime prevalence in schizophrenia ~8%
- Catatonic excitement (agitated catatonia) is the most common type seen today
5. Cognitive Symptoms
- Impairment in working memory, attention, processing speed, executive function
- Deficits in recognition of emotion
- Cognitive impairment is a distinct domain from negative symptoms (modest but consistent correlation)
- Cognitive deficits are often present before first psychotic episode
Prodrome
- Social withdrawal, declining academic/occupational performance
- Attenuated psychotic symptoms (odd beliefs, magical thinking, ideas of reference)
- Disrupted sleep-wake cycle, irritability
- May begin years before overt psychosis
- Early identification and intervention in the prodromal phase is an active area of clinical focus
Course and Prognosis
- Typically characterized by acute psychotic episodes (exacerbations) superimposed on progressively deteriorating baseline functioning
- Prognosis often poor overall
- A small proportion may recover completely
- Antipsychotic drugs significantly reduce relapse rates
Predictors of poor prognosis:
- Male sex
- Prominent negative symptoms
- Younger age at first onset
- Enduring psychosocial stressors and family discord
- Longer duration of untreated psychosis (DUP)
Differential Diagnosis
| Disorder | Key Distinguishing Feature |
|---|
| Brief psychotic disorder | < 1 month duration; return to full baseline |
| Schizophreniform disorder | 1-6 months duration |
| Schizoaffective disorder | Concurrent schizophrenic symptoms + mood syndrome; with ≥2 weeks of psychosis without mood |
| Delusional disorder | Non-bizarre delusions ≥1 month; functioning otherwise not markedly impaired |
| Bipolar disorder with psychosis | Psychosis confined to mood episodes |
| Substance-induced psychosis | Psychosis due to drugs (stimulants, cannabis, PCP, etc.) |
| Autoimmune encephalitis | Especially anti-NMDA receptor encephalitis mimics first-episode psychosis |
| Mood disorder with psychotic features | Mood episode predominates |
Treatment
Antipsychotic Medications
First-Generation (Typical) Antipsychotics:
- Mechanism: D2 receptor antagonism
- Prototype: Chlorpromazine (first antipsychotic), Haloperidol
- Effective for positive symptoms
- NOT effective for negative or cognitive symptoms
- Side effects: extrapyramidal symptoms (EPS) - parkinsonism, akathisia, acute dystonia, tardive dyskinesia; hyperprolactinemia
Second-Generation (Atypical) Antipsychotics:
- Lower D2 receptor occupancy (faster dissociation) + serotonin 5-HT2A antagonism
- Lower rates of EPS and tardive dyskinesia
- Less likely to cause hyperprolactinemia
- Efficacy for positive symptoms is generally NOT better than first-generation
- Important agents:
| Drug | Key Features |
|---|
| Clozapine | Greatest efficacy (including treatment-resistant cases); requires monitoring for agranulocytosis; associated with lowest relapse rates |
| Risperidone | Commonly used; highest prolactin elevation among atypicals |
| Olanzapine | Effective; significant metabolic side effects |
| Quetiapine | Low EPS; sedating |
| Aripiprazole | Partial D2 agonist; weight-neutral |
| Cariprazine | May be superior to risperidone for predominantly negative symptoms |
Long-Acting Injectable (LAI) antipsychotics:
- Associated with greatest reduction in relapse rates (along with clozapine)
- Addresses the major problem of medication non-adherence
Metabolic Monitoring
- Second-generation antipsychotics contribute to obesity and metabolic syndrome in chronic schizophrenia
- Regular monitoring of weight, glucose, lipids is mandatory
Psychosocial Interventions
- Comprehensive psychosocial rehabilitation programs are important for functional outcomes
- Assertive Community Treatment (ACT)
- Cognitive Behavioral Therapy for psychosis (CBTp)
- Family psychoeducation
- Social skills training
- Supported employment
- Prompt use of psychosocial programs at initial onset may improve long-term course
Comorbidities
| Comorbidity | Notes |
|---|
| Depression | Can mimic negative symptoms (important to distinguish); Calgary Depression Scale used |
| Anxiety / PTSD | PTSD amplifies schizophrenia core symptom severity |
| Metabolic syndrome | Worsened by antipsychotic medications |
| Substance use disorders | Common; cannabis especially associated with psychosis exacerbation |
| Cardiovascular disease | Major contributor to reduced life expectancy |
| Suicide | Lifetime risk ~5-6% |
Kaplan & Sadock's Comprehensive Textbook of Psychiatry, pp. 4381-4428
Goldman-Cecil Medicine, International Edition, pp. 3764-3765
Goodman & Gilman's The Pharmacological Basis of Therapeutics, pp. 320-321